Is Elemy still operating as an autism care provider?

No. Elemy exited direct clinical ABA therapy by late 2023 and rebranded to Tilly in November 2023, pivoting to a practice-management SaaS platform for ABA providers after shedding its therapist workforce entirely.

Did Elemy have layoffs?

Yes. Elemy underwent at least four rounds of layoffs in 2022, including a December 5, 2022 cut that eliminated 38 of 40 patient-intake roles as it wound down direct care for a software-only model.

Is Elemy still a $1.15 billion unicorn?

The $1.15-1.2B valuation dates to an October 6, 2021 SoftBank-led $219M Series B. No funding round has been publicly reported since, and the company has shrunk dramatically since that valuation was set.

Could AI replace Tilly, the company formerly known as Elemy?

Tilly's remaining product is billing, scheduling, and documentation software. Rival Rethink Behavioral Health already shipped AI billing (BillAI) and AI session-notes tools in its June 3, 2026 relaunch; Tilly has shown no equivalent AI features.

Who founded Elemy and who owns it?

Elemy was founded in 2019 by Yury Yakubchyk (CEO) and Michael Ragheb, originally as Sprout Therapy. It remains privately held by VC investors including SoftBank Vision Fund 2 from its October 2021 round.

Who is Elemy's/Tilly's biggest competitor?

Rethink Behavioral Health, which relaunched as 'Rethink Everything' with AI billing and session-notes tools on June 3, 2026, alongside CentralReach, are the dominant ABA practice-management platforms Tilly competes against.

United States · United States

Elemy

Former autism-care unicorn now selling ABA practice-management software.

Little protection left

Assessed 29 July 2026 · Evidence as of 29 July 2026

Not much stands between this business and its pressures.

On the recordSince 29 July 2026 · Checkable from by early 2027 · Every call on the record Checkpoint: Any financing, acqui-hire, or shutdown announcement, or a shipped AI feature matching Rethink's

The call

Elemy shed its original clinical business, rebranded as Tilly, and now sells practice-management software into a market two larger players already run.

Elemy (formerly Tilly) makes software that helps therapists and clinics handle billing, scheduling, and patient notes for Applied Behavior Analysis treatment. The company faces two big problems: larger rivals like Rethink and CentralReach control most of the market, and those same rivals are now using AI to automate the exact work that Elemy's software does, which removes the reason customers need Elemy in the first place. The company has been quiet for years with no new funding and no major improvements to its product, so its next move, whether it finds investment, gets bought out, ships AI features to catch up, or shuts down, will likely come within the next few months.

Why

AI pressure: Rethink Behavioral Health's BillAI and AI session-notes tools. Rethink already automates the billing and documentation work that Tilly's software is built to handle. Could AI do the core job? Yes, likely.

Bigger players: CentralReach and Rethink Behavioral Health. Two established ABA software platforms already run most of the market Tilly is trying to enter. Could a giant copy it? Yes, easily.

What protects it. None found: no new funding since 2021, no shipped AI features, no named agency customers or retention data.

What would change this call

Elemy/Tilly announces new funding round or valuation update within 6 months. Would show investors still back the unicorn narrative despite 4.5-year silence.
Elemy/Tilly ships AI billing or session-notes features matching Rethink's June 2026 launch. Would show it can keep pace with the dominant incumbent's product roadmap.
Public shutdown, acqui-hire, or quiet sale announcement involving Elemy/Tilly. Would confirm the wind-down thesis suggested by low headcount and no product launches.

Key numbers

$1.15B SoftBank-led valuation (2021-10-06)
38 of 40 intake roles cut in one layoff (2022-12-05)
No funding round disclosed in over 4 years (2026-07-20)

Named risks

No publicly reported funding round since October 2021, over 4.5 years of financing silence. Severity: high
Headcount collapse from 1,000+ at peak to an estimated 21-50 person team. Severity: high
No major product launch identified in roughly 18 months while rival Rethink ships AI features. Severity: high
Core SaaS functions (billing, scheduling, notes) are exactly what competitor AI tools are automating. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Rethink Behavioral Health	losing to	Shipped AI billing and session-notes tools June 3, 2026, a category Tilly has not matched
CentralReach	losing to	Established ABA practice-management incumbent with no comparable move from Tilly since Nov 2023 rebrand

Questions people ask

Is Elemy still operating as an autism care provider?: No. Elemy exited direct clinical ABA therapy by late 2023 and rebranded to Tilly in November 2023, pivoting to a practice-management SaaS platform for ABA providers after shedding its therapist workforce entirely.
Did Elemy have layoffs?: Yes. Elemy underwent at least four rounds of layoffs in 2022, including a December 5, 2022 cut that eliminated 38 of 40 patient-intake roles as it wound down direct care for a software-only model.
Is Elemy still a $1.15 billion unicorn?: The $1.15-1.2B valuation dates to an October 6, 2021 SoftBank-led $219M Series B. No funding round has been publicly reported since, and the company has shrunk dramatically since that valuation was set.
Could AI replace Tilly, the company formerly known as Elemy?: Tilly's remaining product is billing, scheduling, and documentation software. Rival Rethink Behavioral Health already shipped AI billing (BillAI) and AI session-notes tools in its June 3, 2026 relaunch; Tilly has shown no equivalent AI features.
Who founded Elemy and who owns it?: Elemy was founded in 2019 by Yury Yakubchyk (CEO) and Michael Ragheb, originally as Sprout Therapy. It remains privately held by VC investors including SoftBank Vision Fund 2 from its October 2021 round.
Who is Elemy's/Tilly's biggest competitor?: Rethink Behavioral Health, which relaunched as 'Rethink Everything' with AI billing and session-notes tools on June 3, 2026, alongside CentralReach, are the dominant ABA practice-management platforms Tilly competes against.

Timeline

2026-06-03Rival Rethink Behavioral Health launches AI billing (BillAI) and AI session-notes tools
2023-11Elemy completes rebrand to Tilly, pivots fully to ABA practice-management SaaS
2022-12-05Layoffs cut 38 of 40 patient-intake roles as direct-care wind-down accelerates
2022-04Elemy launches Ecademy, paid RBT certification program in CA, TX, FL
2021-10-06Elemy hits unicorn status with $219M SoftBank-led Series B at $1.15B valuation
2019Company founded as Sprout Therapy by Yury Yakubchyk and Michael Ragheb

Revision history

29 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

Warner Bros. Discovery Inflection AI Story Protocol